Adapthealth Corp

AHCO remains in a Stage 2 advance with clear higher highs and higher lows reinforced by a recent momentum breakout on volume. Upward‐sloping EMAs confirm medium-term bullish bias and low transition risk, but price is currently extended into overbought territory and testing prior resistance, reducing immediate entry edge. Execution should be deferred, stalking for a pullback into the rising EMA support zone near the breakout level.

• ↑Q1 2026 revenue $819.8M (+5.4% YoY), beat guidance by $22M
• ↑Over 10 million patients in capitated contracts driving $200M+ in recurring revenue
• ↓Q1 net loss widened to $16M amid elevated labor costs